Two Antagonistic Microtubule Targeting Drugs Act Synergistically to Kill Cancer Cells
Open Access
- 6 August 2020
- Vol. 12 (8), 2196
- https://doi.org/10.3390/cancers12082196
Abstract
Paclitaxel is a microtubule stabilizing agent and a successful drug for cancer chemotherapy inducing, however, adverse effects. To reduce the effective dose of paclitaxel, we searched for pharmaceutics which could potentiate its therapeutic effect. We screened a chemical library and selected Carba1, a carbazole, which exerts synergistic cytotoxic effects on tumor cells grown in vitro, when co-administrated with a low dose of paclitaxel. Carba1 targets the colchicine binding-site of tubulin and is a microtubule-destabilizing agent. Catastrophe induction by Carba1 promotes paclitaxel binding to microtubule ends, providing a mechanistic explanation of the observed synergy. The synergistic effect of Carba1 with paclitaxel on tumor cell viability was also observed in vivo in xenografted mice. Thus, a new mechanism favoring paclitaxel binding to dynamic microtubules can be transposed to in vivo mouse cancer treatments, paving the way for new therapeutic strategies combining low doses of microtubule targeting agents with opposite mechanisms of action.Keywords
Funding Information
- Institut National Du Cancer (PLBIO16186)
This publication has 43 references indexed in Scilit:
- End-binding proteins sensitize microtubules to the action of microtubule-targeting agentsProceedings of the National Academy of Sciences, 2013
- Axonal transport deficits and neurodegenerative diseasesNature Reviews Neuroscience, 2013
- Pharmacological Inhibition of LIM Kinase Stabilizes Microtubules and Inhibits Neoplastic GrowthCancer Research, 2012
- The proliferation rate paradox in antimitotic chemotherapyMolecular Biology of the Cell, 2012
- Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cellsGynecologic Oncology, 2011
- Mitosis is not a key target of microtubule agents in patient tumorsNature Reviews Clinical Oncology, 2011
- Microtubule-binding agents: a dynamic field of cancer therapeuticsNature Reviews Drug Discovery, 2010
- The NCI60 human tumour cell line anticancer drug screenNature Reviews Cancer, 2006
- Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination StudiesPharmacological Reviews, 2006
- Tubulin tyrosination is a major factor affecting the recruitment of CAP-Gly proteins at microtubule plus endsThe Journal of cell biology, 2006